Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 21, 2026 · Filed Oct 23, 2026
Palvella Therapeutics's Chief Operating Officer sold $253K of Palvella Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$252,559
Shares × reported transaction price
78 days after results of Aug 4, 2026, 15 days before results of Nov 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $126.58 on Oct 21, 2026, 80% above its 52-week low and 20% below its high, after a 16% drop over the previous 30 trading days
52-week range $70.43 (Oct 27, 2025) to $158.13 (Sep 22, 2026), 64% of the way up, from 250 adjusted closes. 30 trading days earlier: $151.34 on Sep 9, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +15.9% | −1.7% | +17.6% |
Past results only. Not a forecast.
Insider filing
Traded Nov 10 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Nov 10 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Jeffrey S Martini (Chief Scientific Officer) sold ~$16K of Palvella Therapeutics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
